Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

ONC's latest stock split occurred on May 25, 2018

The company executed a 1-for-9 stock split, meaning that for every 9 shares held, investors received 1 new share.

Before the split, ONC traded at 0.95 per share. Afterward, the share price was about 10.13.

The adjusted shares began trading on May 25, 2018. This was the only stock split in ONC's history.

Last Splits:
May 25, 2018
1-for-9
Pre-Split Price
9.025 0.95
Post-Split Price
10.13
Before
After
Last Splits:
May 25, 2018
1-for-9

Oncolytics Biotech Inc
Stock Splits History

ONC Stock Splits Timeline
May 25, 2018
May 25, 2018
Split 1-for-9
/0.11111111111111
Pre-Split Price
9.025 0.95
Post-Split Price
10.13
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.74 45.74 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
58.49 58.49 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Oncolytics Biotech Inc
Glance View

Market Cap
173.1m CAD
Industry
Biotechnology

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

ONC Intrinsic Value
Not Available
Back to Top